Investigates the effectiveness of the Project Extension for Community Healthcare Outcomes (ECHO) diabetes program by analyzing FQHCs across California and Florida, revealing reductions of health disparities in diabetes as well as other patient/provider-related benefits.

Examines the real-world impact of CGM utilization on glycemic management and healthcare resource utilization (HCRU) through a retrospective observational study of claims data from fully insured private and Medicare Advantage beneficiaries, displaying improved clinical outcomes that may translate to reductions of costly HCRU.

Reviews CGM utilization data in type 2 diabetes patients with and without insulin treatment — exemplifying how device usage cuts hospitalizations and leads to improved glucose control.

Compiles peer-reviewed articles and abstracts demonstrating the impact interpretation of a new CGM-related metric, “Time in Range.”

Employs in-depth interviews and surveys to highlight the need for increased education surrounding CGM utilization education and changes to diabetes care management.

Assesses changes in HbA1c levels among non-insulin and insulin-requiring type 2 diabetes primary care patients prescribed a CGM , finding statistically significant reductions in mean HbA1c levels. Patients who visited a clinical pharmacist during their clinic visit exhibited greater reductions in HbA1c levels.

Reviews the evidence base of the benefits of CGM usage among individuals with type 2 diabetes treated with basal insulin only and/or noninsulin therapies and finds CGM use is associated with improvements in HbA1c and/or other key outcome measures.

Describes the benefits and limitations of CGM use for diabetes treatment, CGM usage in clinical settings, and the application of CGM to advanced diabetes technology.

Studies the clinical outcomes of two CGMs (Dexcom and FreeStyle Libre) in people with type 1 and type 2 diabetes and finds similar rates of acute diabetes events, hospitalizations, and HbA1c reductions between these devices.

Finds that patients with gestational diabetes using CGMs were more likely to have lower HbA1c levels at the end of pregnancy, experience less gestational weight gain, and give birth to infants with lower birth weights compared to those using blood glucose monitoring. However, the evidence is limited by the small number and size of the studies reviewed.

Finds that CGM use among pregnant individuals with diabetes is associated with lower HbA1c levels, cesarean section rates and neonatal birth weight.

Evaluates the benefit of CGM use and finds that seven years later, A1c was significantly lower for those who gained access to a CGM within the first year of type 1 diabetes diagnosis versus those with later CGM use or none at all.